Navigation Links
ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
Date:9/10/2009

IRVINE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the NewsMakers in the Biotech Industry Conference at 11:30 a.m. Eastern Time on September 16, 2009, at the Millennium Broadway Hotel in New York, NY.

ISTA's Chief Financial Officer and Vice President of Corporate Development Lauren Silvernail will provide an update on the Company's commercial and clinical progress. To access the live audio broadcast, or the subsequent archived recording, log ontohttp://www.istavision.com. Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website athttp://www.istavision.com.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Resources, one of the world,s leading research and ... that, owing to the launches of several new ... more than sevenfold from $790 million in 2008 ... States, France, Germany, Italy, Spain, the United Kingdom ... Atrial Fibrillation finds that a strong ...
(Date:12/11/2009)... ROCKVILLE, Md., Dec. 11 EntreMed, Inc. ... of $1.7 million in royalty revenue from sales ... estimated royalty revenue of $3.3 million. In ... quarter and projected revenue for fiscal 2009. ... the third quarter will be reflected in the ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
Breaking Biology Technology:The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... SOUTH SAN FRANCISCO, Calif., Sept. 4, Dow AgroSciences ... Company (NYSE: DOW ), and Exelixis Plant ... EXEL ), announced today,that the companies have ... purchase of selected assets by Dow AgroSciences,affiliate Agrigenetics ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a global leader ... system, announced today that Sam Owusu-Akyaw,Osteotech,s President and ... Company,s strategic direction and market opportunities at the ... Owusu-Akyaw is,scheduled to present at 2:00 p.m. Eastern ...
... The most powerful inflammation fighter of any known botanical now widely ... ... 4 BSP Pharma Inc.,based in Egg Harbor Township, NJ, has announced ... Vitamin,Shoppe stores ( http://www.vitaminshoppe.com ) nationally as well as at,select GNC stores ...
Other Biology Technology:Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC 2
(Date:12/14/2009)... the United Nations Framework Convention on Climate Change ... hosted the ,Bend the Trend, event on Sunday ... and premiere the screening of the new ,Environmental ... Europe, a joint project of the European Environment ... ESA, is a series of short films showing ...
(Date:12/13/2009)... Biologists have identified plant enzymes that may help to ... to use water more efficiently. The finding could help ... gases. , Plants take in the carbon dioxide they ... surface of leaves. But for each molecule of the ... these same openings. The pores can tighten to save ...
(Date:12/13/2009)... have discovered five genetic variants that are associated with ... an international consortium of 96 scientists from 63 centres ... molecular basis of lung diseases. , The new findings ... Chronic Obstructive Pulmonary Disease (COPD) and asthma. In the ... because the molecular pathways that affect the health of ...
Breaking Biology News(10 mins):'Environmental Atlas of Europe' unveiled at COP15 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3New genes for lung disease discovered 2Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 1Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 2Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 3UC nanotech researchers develop artificial pore 10127 1UC nanotech researchers develop artificial pore 10127 2Sogeti USA Grows to Ensure Industry Expertise for Clients 58394 1Sogeti USA Grows to Ensure Industry Expertise for Clients 58394 2Sogeti USA Grows to Ensure Industry Expertise for Clients 58394 3
... Trees do it. Bees do it. Even environmentally stressed fish ... Department of Zoology is the first in the world to ... , His research may provide the key to the survival ... the ocean ― currently threatened by global warming. , ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... from Princeton University and the Drexel University College of ... breaks down an important amino acid in its quest ... depleting this substance called arginine, the parasite may trigger ... , The scientists believe that shedding light on this ...
Other Biology News:Changing sexes on the sea floor 2Nutrient pollution chokes marine and freshwater ecosystems 2Malaria parasite zeroes in on molecule to enhance its survival, team finds 2Malaria parasite zeroes in on molecule to enhance its survival, team finds 3
Blimp-1 (H-150)...
... ATPase α-1, clone C464.6 GenBank Accession ... Na + /K + ATPase isolated ... medulla Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... routinely evaluated in immunoblot on rat brain ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Biology Products: